– About 1/3 of epilepsy patients fail to respond to drugs, and many of these patients are eligible for potentially curative surgical resection. But most patients won’t undergo the extensive diagnostic and surgical process, as it requires invasive access to the brain and long hospital stays, even though this remains one of the most effective treatments
– NeuroOne Medical (NMTC) could flip this completely, making the diagnostic process shorter and the intervention easier and quicker for doctors and patients. The company’s core technology, a thin-film electrode, has undergone testing at the Mayo Clinic, which is also a major shareholder in the company
– 2018 and 2019 bring big value inflection events for NeuroOne, and few investors have taken note of this newly public company, despite a reasonable valuation and a rapid approval process …View the full post at: Here’s Why The Mayo Clinic Owns 10% of This Unknown Epilepsy Stock with Big Upcoming FDA Catalyst …
Related Articles:
5 Innovators Changing The Lithium Game
5 Innovators Changing The Lithium Game
The Canadian Energy Revolution Is Here
The Hottest Real Estate Market You Never Heard About
